Latest Data Further Support Ibrutinib's Efficacy in CLL

Published December 11, 2013

Latest Data Further Support Ibrutinib's Efficacy in CLL
The oral drug received a Breakthrough Therapy Designation from the FDA in April 2013 for particularly poor prognosis and high-risk CLL or small lymphocytic lymphoma (SLL) patients who carry a deletion in chromosome 17 (17p deletion). … “This is one …
Read more on OncLive

Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2014 Financial …
TUSTIN, CA–(Marketwired – Dec 10, 2013) – Peregrine Pharmaceuticals, Inc. ( NASDAQ : PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results …
Read more on Marketwired (press release)

Genetic variation increases risk of kidney disease progression in African …
The research, led by investigators from the University of Maryland School of Medicine and Johns Hopkins University, may help explain, in part, why even after accounting for differences in socioeconomic background, end-stage kidney disease is twice as …
Read more on The Almagest

Luxury Drug Treatment in Maryland | Call 800-839-1682 For Inquiries — Luxury Drug Treatment in Maryland – Call 800-839-1682 For Inquiries Recovery from addiction is one major challenge to the victims. In fact, it needs proper c…

Find More Drug Treatment Programs In Maryland Information…